Can a genetic test pick the best chemo for triple negative breast cancer?
NCT ID NCT01982448
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two chemotherapy drugs, cisplatin and paclitaxel, given before surgery to 147 women with triple negative breast cancer. The goal was to see if a genetic test called HRD could predict which drug would work better. Researchers measured how much the tumor shrank after treatment to compare the drugs and the test's accuracy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cisplatin and paclitaxel (chemotherapy drugs)
- What this could lead to
- If successful, this could help doctors choose the best chemotherapy for each patient based on a genetic test, improving treatment outcomes for triple negative breast cancer.
- What could go wrong
- This is a phase II trial with only 147 participants, so results may not apply to all patients. The HRD test may not reliably predict response, and the study is already completed, meaning findings are preliminary.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Indiana University- Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center-Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Cancer Center-Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Cancer Center-Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Cancer Center-Rockville Centre
Rockville Centre, New York, 11570, United States
-
Memorial Sloan Kettering Cancer Center-Sleepy Hollow
Sleepy Hollow, New York, 10591, United States
-
Memorial Sloan Kettering Cancer Center-West Harrison
Harrison, New York, 10604, United States
-
Seattle Cancer Alliance at EvergreenHealth
Kirkland, Washington, 98034, United States
-
South Shore Hospital
Weymouth, Massachusetts, 02190, United States
-
University of Alabama
Birmingham, Alabama, 35294, United States
-
University of North Carolina- Lineberger Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
University of Washignton
Seattle, Washington, 98195, United States
-
Universtiy of Pittsburgh- Magee-Womens Hospital
Pittsburgh, Pennsylvania, 15213, United States
-
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new nucleotide analogue boost cancer treatment?